Clinical Trial

A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-17; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2026-03-12
Trial Details
NCT Number NCT07426380
Lead Sponsor Eli Lilly and Company
Conditions Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic, Renal Impairment, Renal Insufficiency, End Stage Kidney Disease
Enrollment 28 participants
Start Date 2026-02-24
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-06